mk-4830
mAbexperimental
Clinical trial activity
9 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jul 11, 2018 (NCT03564691)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- Esophageal Squamous Cell Carcinoma · Phase 1/Phase 2
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Sarcoma · Early Phase 1
- Small Cell Lung Carcinoma · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Early Phase 1
Mechanism of action
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05319730 | Phase 1/Phase 2 (Phase 2) | Feb 27, 2023 | Merck |
| NCT05342636 | Phase 1/Phase 2 (Phase 2) | Jul 27, 2022 | Merck |
| NCT05446870 | Phase 2 | Jul 25, 2022 | Merck |
| NCT06413095 | Early Phase 1 (Phase 1) | Jun 1, 2022 | Merck, Presage Biosciences |
| NCT04938817 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2021 | Merck |
| NCT04924101 | Phase 2 | Jul 15, 2021 | Merck |
| NCT04626518 | Phase 1/Phase 2 (Phase 2) | Dec 17, 2020 | Merck |
| NCT04165083 | Phase 2 | Jan 17, 2020 | Merck |
| NCT03564691 | Phase 1 | Jul 11, 2018 | Merck |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merck | For profit | 9 | 8 | 2 | 2018 |
| Presage Biosciences | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1